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Background:  Trimeresurus stejnejeri venom plasminogen activator (TSV-PA)
is a snake venom serine proteinase that specifically activates plasminogen.
Snake venom serine proteinases form a subfamily of trypsin-like proteinases
that are characterised by a high substrate specificity and resistance to
inhibition. Many of these venom enzymes specifically interfere with haemostatic
mechanisms and display a long circulating half-life. For these reasons several of
them have commercial applications and are potentially attractive
pharmacological tools.
Results:  The crystal structure of TSV-PA has been determined to 2.5 Å
resolution and refined to an R factor of 17.8 (R free, 24.4). The enzyme,
showing the overall polypeptide fold of trypsin-like serine proteinases, displays
unique structural elements such as the presence of a phenylalanine at position
193, a C-terminal tail clamped via a disulphide bridge to the 99-loop, and a
structurally conserved Asp97 residue. The presence of a cis proline at position
218 is in agreement with evolutionary relationships to glandular kallikrein.
Conclusions:  We postulate that Phe193 accounts for the high substrate
specificity of TSV-PA and renders it incapable of forming a stable complex with
bovine pancreatic trypsin inhibitor and other extended substrates and inhibitors.
Mutational studies previously showed that Asp97 is crucial for the
plasminogenolytic activity of TSV-PA, here we identify the conservation of
Asp97 in both types of mammalian plasminogen activator — tissue-type (tPA)
and urokinase-type (uPA). It seems likely that Asp97 of tPA and uPA will have a
similar role in plasminogen recognition. The C-terminal extension of TSV-PA is
conserved among snake venom serine proteinases, although its function is
unknown. The three-dimensional structure presented here is the first of a snake
venom serine proteinase and provides an excellent template for modelling other
homologous family members.
Introduction
The fibrinolytic system consists of a serine proteinase
cascade that is mainly involved in the dissolution of
blood clots [1]. It recently became apparent, however,
that the components of this system also have a role in
processes requiring cell migration. These processes include
wound healing, tissue remodelling, angiogenesis, embryo-
genesis, tumor cell and pathogen invasion [2–4]. A
crucial event in the fibrinolytic cascade is the activation
of plasminogen to plasmin. Highly specific proteinases,
the plasminogen activators, activate plasminogen to the
less specific serine proteinase plasmin, which in turn
degrades fibrin(ogen) and other components of the extra-
cellular matrix. Plasmin exerts this activity either directly
or indirectly upon activation of a cascade of metallopro-
teinases [5]. The physiological generation of plasmin is
highly localised to fibrin clots and tightly controlled. Key
mechanisms to regulate the activity of the fibrinolytic
system involve modulation of the synthesis of the plas-
minogen activators, their inhibitors (serpins) and their
substrate/regulatory molecule, fibrinogen. Furthermore,
the cell-surface expression of receptors for plasminogen
activators and plasminogen can also be controlled [2].
In all mammalian species investigated so far, two distinct
plasminogen activators have been identified: urokinase-
type plasminogen activator (uPA) and tissue-type plasmino-
gen activator (tPA). These enzymes activate plasminogen
by limited proteolysis at the Arg561–Val562 bond. Both
enzymes are very closely related, despite having distinct
physiological roles [6]. The activity of uPA is localised to
the cell surface, whereas that of tPA is mainly directed
against intravascular fibrin. Invasive human pathogens
produce plasminogen activators of a different type, which
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activate plasminogen to plasmin through conformational
changes [4,7]. Examples of this second class of plasminogen
activators are streptokinase and staphylokinase [8].
Plasminogen activators of both types represent important
pharmacological tools for the treatment of myocardial
infarction and other vascular diseases, which account for
one-third of the total number of deaths each year [9–11].
Their clinical application has provided a dramatic improve-
ment in the treatment of thrombotic events. However, the
pharmacokinetics and side effects of these activators can
limit their administration. Much effort is being made to
improve the half-life of the currently available plasmino-
gen activators and to reduce their side effects, such as
reocclusion and bleeding [12,13].
Snake venoms contain a great variety of enzymes that are
toxic. These enzymes mediate their toxicity by either stim-
ulating or inhibiting haemostatic mechanisms. Amongst
them are diverse proteinases that affect blood coagulation,
fibrinolysis, platelet function, vascular integrity, and provoke
haemorrhage [14]. The fibrinolytic activating components
in snake venoms mostly achieve inhibition of blood coagu-
lation due to the action of fibrin(ogen) degrading enzymes.
In other cases, fibrinolysis is stimulated indirectly as a con-
sequence of the release of tPA from endothelial cells. A true
plasminogen activator from snake venom, however, has
only recently been found and cloned [15].
This enzyme (TSV-PA), which was originally isolated
from Trimeresurus stejnejeri venom, is a serine proteinase
that enzymatically activates plasminogen. TSV-PA exhibits
a high degree of sequence identity to other venom pro-
teinases: 66% identity to a protein C activator, 64% to
batroxobin, and 60% to a factor V activator from Russel’s
viper venom. Nevertheless, despite this similarity, TSV-PA
neither activates nor degrades protein C, prothrombin or
factor X. In addition, TSV-PA does not clot fibrinogen,
nor does it show fibrino(geno)lytic activity in the absence
of plasminogen [16]. On the other hand, TSV-PA is only
23% identical to the catalytic domain of tPA but shares
its substrate specificity. Unlike plasminogen activation
by tPA, activation by the venom enzyme is not stimu-
lated by fibrin fragments and is about 50-fold lower than
that observed with tPA stimulated with fibrin fragments.
In common with other snake venom serine proteinases,
however, TSV-PA shows a remarkable resistance to inhi-
bition and may be expected to have a long circulating
half-life. The bovine pancreatic trypsin inhibitor (BPTI,
also called aprotinin) and the soybean trypsin inhibitor
have little or no effect on TSV-PA, and antithrombin III/
heparin or hirudin are also ineffective [16]. TSV-PA also
lacks the sequences that have been demonstrated to be
essential for the interaction of tPA (Lys-His-Arg-Arg) and
uPA (Arg-Arg-His-Arg) with plasminogen activator inhibitor
type I (PAI-1) [17,18]. Moreover, TSV-PA does not contain
the kringle or finger domains of tPA, which carry critical
determinants for clearance by hepatic receptors [19,20].
In an attempt to understand the determinants of TSV-PA’s
substrate selectivity and resistance to inhibition, we have
solved the crystal structure of TSV-PA in complex with
Glu-Gly-Arg-chloromethylketone. Here, we give a detailed
description of the TSV-PA structure, emphasising its high
substrate specificity and its relevance to structure-based
drug design. We also present a model of its interaction with
the plasminogen activation loop, providing further insight
into the mechanism underlying plasminogen activation.
Most importantly, this structure is the first structure of a
snake venom serine proteinase and provides an excellent
template for modelling other highly homologous members
of this subfamily of enzymes which have diverse commer-
cial and pharmacological applications.
Results
Overall structure
The TSV-PA structure has been refined to an R value of
0.178 (R free = 0.244) at 2.5 Å resolution. TSV-PA is
roughly spherical with a radius of 25 Å. The overall struc-
ture is folded into two six-stranded β barrels connected by
three trans segments, showing the typical fold of a trypsin-
like serine proteinase (Figure 1). The surface is made up of
various turn structures and loops, and two short α helices
from residues 165–173 and residues 235–244 (Figure 1).
The active-site cleft and the catalytic residues are located at
the junction of both barrels, which are thought to have
evolved by gene duplication [21]. A structural alignment
shows that the topology of TSV-PA is particularly similar to
that of tPA and glandular kallikrein, despite the relatively
low sequence homology to both proteinases (Figure 2).
Optimal superposition of TSV-PA with tPA and glandular
kallikrein results in 130 and 164 topologically equivalent
Cα atoms with root mean square (rms) deviations of 0.87 Å
and 0.69 Å, respectively, if only Cα carbon atom pairs
within 1.5 Å are included (Figure 2). This is in agreement
with evolutionary relationships.
An amino acid sequence alignment of TSV-PA with tPA,
uPA, batroxobin, glandular kallikrein, trypsin and chy-
motrypsin is presented in Figure 3. The numbering is
based on the topological equivalence to chymotrypsino-
gen [22]. TSV-PA exhibits 64% identity to batroxobin,
and the alignment only requires a two-residue insertion
around the 174 loop (Figure 3). Compared to trypsin
(40% sequence identity) TSV-PA presents four inser-
tions, at positions 36, 95a, 172a and 218, and a seven-
residue C-terminal extension, which is well conserved
among snake venom serine proteinases (Figure 3). Unlike
tPA and uPA, the basic residues essential for PAI-1
binding are not present in TSV-PA (residues 35–39).
The sequences around the 99-loop, the 60-loop and the
148-loop are also shorter than in tPA and uPA, and a
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four-residue insertion at position 205 is missing, as in
trypsin (Figure 3). At the amino acid sequence level,
TSV-PA shows 36.5% identity to its presumed molecular
ancestor, namely glandular kallikrein (Figure 3) [23].
Like batroxobin, TSV-PA exhibits a C-terminal exten-
sion (Figure 3). Other serine proteinases, such as leuko-
cyte elastase, cathepsin G and factor Xa, also have C-ter-
minal extensions, although these do not show sequence
similarity to TSV-PA. Moreover, the tail structures of
these serine proteinases remain unsolved, probably due
to autocatalytic C-terminal trimming [24–26].
The seven-residue C-terminal extension of TSV-PA, which
is highly conserved among snake venom serine proteinases,
is well defined in the structure (Figures 1 and 3). This
C-terminal extension runs through a depression between
the C-terminal helix and the 99-loop. Moreover, it is cova-
lently linked to the 99-loop via a disulphide bridge also
conserved in snake venom proteinases (Cys91–Cys245e).
Residues 245c–245g from the C-terminal extension are
arranged in an extended strand running antiparallel to
residues 235–244 of the C-terminal helix (Figures 1 and 2).
Residues 245–245b connect the C-terminal extension with
the C-terminal helix forming an open 1,4 turn. The C-ter-
minal Pro245g forms a salt bridge to the distal amino group
of Lys101.
As in almost all of the other active chymotrypsin-like
serine proteinases, the N-terminal residue of TSV-PA
(Val16) forms an internal salt bridge between its α-ammo-
nium group and the sidechain carboxylate group of
Asp194. Interestingly, residue 17 is a phenylalanine instead
of a usually conserved medium-sized branched amino
acid, typically isoleucine or valine, with its benzyl group
buried in the activation domain of the enzyme. Like-
wise, human tPA is unusual in that it presents a lysine at
this position (Figure 3).
With its seven arginine and 13 lysine residues opposed by
nine glutamates and 17 aspartates, TSV-PA is a relatively
acidic molecule (calculated pI = 5.67). Apart from residues
Asp102, Asp189 and Asp194, which are involved in the
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Figure 1
Stereoview ribbon plot of TSV-PA. The view
(referred to as the standard orientation) is
towards the active-site cleft, which runs from
left to right across the molecular surface. The
Glu-Gly-Arg-chloromethylketone inhibitor and
the disulphide bridge connecting the C-
terminal extension with the 99-loop are
depicted as ball-and-stick models. The N and
C termini are marked; the numbers
correspond to the loops surrounding the
active-site cleft. β Sheets are shown in blue,
α helices in red and loops in yellow. (The
figure was prepared with MOLSCRIPT [51]
and rendered using RASTER3D [52].)
Figure 2
Stereoview superposition of Cα plots of the
catalytic domain of human tPA (blue), porcine
glandular kallikrein (yellow) and TSV-PA (red).
The view and figure labels are as in Figure 1
(standard orientation). The
chloromethylketone inhibitor (green) was
added in the same orientation as when bound
to TSV-PA. (The figure was prepared with
MOLSCRIPT [51] and rendered using
RASTER3D [52].)
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Figure 3
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Structure
Sequence alignments. The amino acid sequences of human uPA [35],
human tPA [37], TSV-PA [15], batroxobin [53], porcine glandular
kallikrein [27], bovine trypsin [28] and bovine chymotrypsin [54] were
aligned according to their topological equivalence. The numbering refers
to chymotrypsinogen. Secondary-structure elements are indicated below
the sequence: α helices are shown as red cylinders and β strands as
blue arrows. Residues of the catalytic triad are marked by red triangles.
Particularly close sequence homologies between all seven proteins are
given in blue boxes, where identities are typed in red. (The figure was
prepared using the program ALSCRIPT [55].)
catalytic triad or in the formation of buried salt bridges, all
other charged sidechains are exposed to the bulk solvent.
Residues 26, 59, 74, 88, 97, 101, 137, 143, 149, 153, 174
and 245g form surface-exposed intramolecular salt bridges.
The juxtaposition of Glu98, Asp102, Asp189, Gln222 and
Glu224 produces a rather negative electrostatic potential
around the active-site cleft (Figure 4).
Loops surrounding the active site
The entrance to the active-site cleft of TSV-PA is
restricted by several surface loops. These loops and their
distinct properties determine the basis for its substrate
specificity. In the following discussion, the loops sur-
rounding the active site will be described and addressed
anticlockwise, where quarters are denoted according to
the standard orientation as shown in Figure 1.
To the north of the active site the 99-loop (a β-hairpin
loop as seen in other serine proteinases) projects out of
the molecular surface and forms a highly charged rim
(Lys-Lys-Asp-Asp-Glu-Val) (Figures 4 and 5). A salt
bridge between Asp97 and Arg174 stabilises this loop and
occludes the S4 binding pocket (Figures 4 and 5). The
99-loop is further held in place by the disulphide bridge
between Cys91 and Cys245e from the C-terminal exten-
sion. This bridge is strictly conserved among snake
venom serine proteinases.
To the west of the active site and adjacent to the 99-loop,
the 174-loop presents, as in tPA, an arginine at position
174. Arg174 mediates the salt bridge to Asp97 described
above, which is crucial for the plasminogenolytic activity
of TSV-PA (Figures 4 and 5) [16]. Trp173 projects into
the active site and would interfere with P4 residues of
peptide substrates binding in an extended conformation
(Figures 4 and 5). The sidechain of Asn178, which repre-
sents the single carbohydrate linkage site of TSV-PA, is
distant from the active-site cleft and points away from it.
An oligosaccharide should therefore not interfere with
productively bound macromolecular substrates, in agree-
ment with the negligible effects of glycosylation on TSV-
PA’s activity [16].
The access to the active site is further restricted to the
west by loop segment 217–225 (Figure 5). Compared to
trypsin, this segment contains an insertion at position 218
and a proline at position 219, which is in the cis conforma-
tion (Figure 3). The mainchain of this loop follows the
conformation seen in the structure of the ancestral mol-
ecule glandular kallikrein, which likewise exhibits an
insertion and a cis Pro219 (Figure 5). Moreover, Pro219 is
conserved among all snake venom serine proteinases. In
our structure, the carbonyl group of cis Pro219 points
towards the bulk of the solvent away from the P1 pocket.
This conformation is also seen in the structure of glandu-
lar kallikrein [27]. In other trypsin-like serine proteinases,
however, this carbonyl group provides an anchoring point
for guanidinium groups entering the specificity pocket.
The sidechain of His218 is not well defined in the density
and is therefore assumed to be mobile.
The southern boundary of the active-site cleft of TSV-PA
is mainly formed by the fully defined ‘autolysis’ loop.
This loop, which has the same length as in trypsin, tPA
and uPA, packs against the molecular body by looping
around the sidechain of Arg143. It is noteworthy that the
loop segment 149–151 of tPA and uPA is shifted upwards
compared to that in TSV-PA. With this backbone confor-
mation, the phenolic sidechain of Tyr151 of tPA and uPA
extends into the S′2 subsite, thereby restricting it. In TSV-
PA this S′2 locus is occupied by Phe193, and the autolysis
loop of TSV-PA adopts a different conformation, so that
its Tyr151 does not collide with Phe193 in the S′2 subsite
(Figures 5 and 6).
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Figure 4
Solid-surface stereoview representation of the
electrostatic potential around the active site of
TSV-PA shown in the standard orientation.
Colouring is according to the calculated
electrostatic potential contoured from –8 kT/e
(intense red) to +8 kT/e (intense blue). The
plasminogen activation loop is depicted as a
stick model, with oxygens in red, nitrogens in
blue, sulphur atoms in green, and all other
atoms in white. The clustering of negative
charges (mainly originating from residues
Glu98, Asp102, Asp189, Gln222 and
Glu224) around the active site is apparent.
(The figure was made using the programme
GRASP [56].)
Adjacent to the autolysis loop and behind the 37-loop
resides the 70-loop. In TSV-PA this loop is topologically
similar to the calcium-binding loop of trypsin and related
proteinases [28]. In contrast to the digestive enzymes and
the clotting factors IXa and Xa [29,30], however, the
calcium site of TSV-PA is occupied by a water molecule.
In TSV-PA, the putative calcium coordination ligands (i.e.
the sidechains of residues 70 and 80 and the carbonyl
groups of residues 72 and 75) are either not present or
adopt an unfavourable conformation. This is in agreement
with the activity of TSV-PA not being affected by high
concentrations of EDTA [16].
To the east of the active site, the 37-loop presents a one-
residue insertion compared to trypsin (Figure 3). It is,
nevertheless, small and well defined, and it lacks the
characteristic insertions of tPA and uPA that are respon-
sible for PAI-1 binding. In TSV-PA, residue 32 is a valine
and residue 40 is a phenylalanine. Thus, TSV-PA (like
tPA) lacks a specific ‘zymogen triad’ (Asp194-His40-Ser32)
as present in trypsin and chymotrypsin to stabilise the
zymogen form [31,32].
To the north and adjacent to the 37-loop resides the
60-loop. This loop is short and extends along the mole-
cular body in a similar manner to that observed in trypsin.
The active-site cleft
The active-site cleft is delimited to the north by four
exposed loops: the 174-loop, the 99-loop, the 60-loop and
the 37-loop (Figure 5). To the south, four other surface
loops border the active site: the 217–220 loop, the 192–193
segment, the autolysis loop (148-loop) and the calcium
loop (70-loop; Figures 5 and 6).
The residues of the catalytic triad, Ser195, His57 and
Asp102, are arranged in the active-site cleft as in trypsin and
tPA. The specificity pocket (S1) is made up of the segments
213–220 (entrance frame), 189–195 (the basement), and
225–228 (the back of the pocket) (Figure 5). This S1 pocket
shows considerable similarity to glandular kallikrein: the
backbone conformation of the 213–220 segment is virtually
identical, and the threonine at position 190 and the glycine
at position 226 are conserved (Figures 3 and 5).
The S2 site is constricted by residues Val99 and Glu98 pro-
truding from the 99-loop, which in fact forms the north rim
of the S2 pocket (Figure 4). This leaves only enough space
for small residues to be accommodated in the S2 subsite. A
salt bridge between residues Asp97 and Arg174 occludes
the S4 subsite (Figure 5). To the east of Ser195, the S′1 site
is delimited by Leu41 and the Cys42–Cys58 disulphide
bridge (Figure 5). This cavity is rather open and exposed
to the solvent. The S′2 subsite is flattened by residue
Phe193 protruding into the active-site cleft (Figures 5 and
6). In fact, structural alignments with other serine pro-
teinases in complex with macromolecular inhibitors show
that extended binding would be impossible due to steric
clashes with residue Phe193. When the complex of leuko-
cyte elastase with turkey ovomucoid inhibitor [24] is aligned
with the TSV-PA structure, residue P′2 (tyrosine) of the
inhibitor clashes with Phe193 of TSV-PA (Figure 7). Simi-
larly, when the kallikrein–BPTI complex [27] is aligned
with TSV-PA, residue P′2 (arginine) of BPTI extends
through the aromatic ring of Phe193 in TSV-PA (Figure 7).
Inhibitor binding
Relatively clear density was seen for the chloromethylke-
tone inhibitor Glu-Gly-Arg-CH2-Cl covalently bound to the
active site of TSV-PA before including it in phasing. The
continuous electron density and also the distances between
the carbonyl carbon and Ser195 Oγ, and between the meth-
ylene carbon and His57 Nδ (1.44 Å and 1.5 Å, respectively)
clearly indicate the formation of covalent bonds.
The inhibitor backbone juxtaposes TSV-PA segment 214–
217 forming a short antiparallel β sheet (Figure 5). GluI1 O
(where I indicates a residue of the inhibitor) forms a
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Figure 5
Stereoview stick model of the TSV-PA–inhibitor
complex around the active site. Carbon atoms
of the protein are shown in yellow, and carbon
atoms of the inhibitor are in magenta; oxygen
atoms are in red and nitrogen atoms in blue.
Water molecules are drawn as orange spheres.
The inhibitor stretches across the active site,
which is restricted by several surface loops.
Residues from these loops protruding into the
active site are labelled. To the east, residue
193 restricts access to the S′2 pocket. A salt
bridge crucial for the plasminogenolytic activity
of TSV-PA is seen to the west
(Asp97–Arg174). (The figure was prepared
using the programme MAIN [48].) 
favourable hydrogen bond with Gly216 N (3.7 Å), and ArgI3
N forms one with Ser214 O (3.2 Å). The ArgI3 sidechain
occupies the specificity pocket making a salt bridge to the
sidechain of Asp189 (Figure 5). The bottom of the pocket is
quite voluminous due to the presence of a glycine residue at
position 226. This is in agreement with TSV-PA’s prefer-
ence for arginine at P1 [16]. P2 residue GlyI2 nestles into the
restricted S2 pocket, which allows little space for sidechains
(Figure 4). No clear density was observed for the sidechain
of GluI1 even after performing simulated annealing (using
the programme X-PLOR) [33] or ‘quicking’ (using the pro-
gramme MAIN) [34] runs and calculating omit maps. In
fact, the faint electron density allows positioning of the
GluI1 sidechain in two different conformations. In one con-
formation, the sidechain of GluI1 points to the south in a
manner similar to that seen in the urokinase structure [35],
but its sidechain is rotated so as to make a hydrogen bond
with ArgI3 Nε and not to collide with His218 (Figure 5). In
the other possible conformation, the sidechain of GluI1
points to the north into the S4 pocket making a favourable
contact with the Nε of Arg174. The N-terminal group of P3
would then point to His218 (not shown).
Plasminogen binding
Complexes of the canonical protein inhibitors with their
target/cognate proteinases are generally considered reliable
structural models for proteinase–substrate interactions [36].
A model for the interaction of the plasminogen activation
loop with the active site of TSV-PA was constructed. We
based our study on the model of the plasminogen activation
loop presented by Lamba et al. [37] and superimposed it
onto the active-site cleft of TSV-PA. Lamba et al. took the
backbone conformation of the BPTI loop which interacts
with trypsin’s active site, and mutated the corresponding
residues for the plasminogen activation loop (Cys-Pro-Gly-
Arg/Val-Val-Gly-Gly-Cys, where the slash indicates the
activation cleavage site). This loop is circularised by a disul-
phide bridge between the flanking cysteine residues, which
imposes considerable restrictions on its conformation.
To our surprise, no structural rearrangements were neces-
sary upon superposition of this plasminogen activation
loop into the active site of TSV-PA. The backbone of the
plasminogen activation loop forms a short canonical anti-
parallel β sheet with TSV-PA segment 214–217 (Figure 4).
Residue P1 (arginine) occupies the specificity pocket in a
similar way to that previously described for the covalently
bound inhibitor (see above, Figure 4). P2 (glycine) fits into
the small S2 site, and P3 (proline) makes a kink avoiding
collision with Arg174. P′1 (valine) partially fills the S′1
cavity, and P′2 (valine) extends alongside P′1 (valine) into
the S′1 pocket escaping collision with Phe193. The follow-
ing P′3 and P′4 glycine residues of the plasminogen activa-
tion loop must fold back to allow disulphide bridge
formation between P4 (cysteine) and P′5 (cysteine) of plas-
minogen (Figure 4).
Discussion
Snake venom serine proteinases are a trypsin-like sub-
family of enzymes that share a high degree of sequence
identity despite exhibiting a remarkably high substrate
selectivity. As an example, TSV-PA shares extensive
sequence homology to other snake venom serine protein-
ases (60–70%; Figure 3) but nevertheless shows a remark-
ably high substrate specificity towards plasminogen [16].
The overall architecture of TSV-PA resembles that of
trypsin (Figure 1). Although trypsin can also activate
plasminogen in vitro [38], TSV-PA can be readily distin-
guished from trypsin by its high substrate specificity and
its insensitivity to soybean trypsin inhibitor [16]. Com-
pared to trypsin, TSV-PA contains a well defined C-termi-
nal extension, which is linked by a disulphide bridge to
the main body of the enzyme (Figures 1 and 2). This
extension is typical for snake venom proteinases, and its
amino acid sequence is highly conserved (Figure 3). Other
serine proteinases also contain C-terminal extensions (i.e.
factor Xa, cathepsin G and leukocyte elastase), but their
sequences are not conserved. The biological significance
of these insertions is presently unknown.
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Figure 6
Stereoview section of the model around
residues His192 and Phe193 including the
final 2Fobs–Fcalc electron-density map
contoured at 1σ. The atom colours are the
same as in Figure 5. Residue Phe193 is
unique to TSV-PA; in all other well
characterised serine proteinases this position
is conserved and occupied by a glycine
residue. (The figure was made with the
programme MAIN [48].)
The absence of other insertions or deletions (Figure 3)
and the lack of charged surface patches indicate the
absence of exosites in TSV-PA. Taken together, this data
imply that the high substrate selectivity of TSV-PA arises
from a carefully assembled active site. The access to TSV-
PA’s active site is indeed restricted by several surface
loops (see Results section), and canonical binding can
only occur between the S3 and S′1 subsites, with the S2
position occupied by a small amino acid (Figure 7). The
S4 pocket is occluded by Trp173, and the S′2 site by
Phe193 (Figure 7). This correlates with TSV-PA’s high
activity towards small chromogenic substrates, as com-
pared to a lower reactivity towards extended macromolec-
ular substrates and inhibitors [16].
In the TSV-PA structure, the P3 residue of the inhibitor is
not well defined and modelling studies suggest that it
could adopt two different conformations. A novel inhibitor
binding mode, where the sidechain of P3 points towards
the 99-loop and into the S4 pocket, supports very recent
studies on the subtle specificity differences of uPA and
tPA [39,40]. As in tPA, the 99-loop presents an ‘acidic
edge’ that confers a hydrophilic character to the S4 pocket.
In uPA this pocket is more hydrophobic. Such differences
can be exploited to design selective inhibitors. Despite
their striking similarities, the roles of the physiological
plasminogen activators (uPA and tPA) are distinct, and
many studies suggest that selective inhibition of either
enzyme might have a beneficial therapeutic effect [41].
To identify the functional determinants of TSV-PA,
Zhang et al. [16] undertook mutational studies on three
short peptide fragments showing important sequence dif-
ferences to batroxobin and other venom serine proteinases
(residues 60–64, 96–98 and 172a–176; Figure 3). When
these TSV-PA sequences were replaced by the equivalent
batroxobin residues, none generated fibrinogen-clotting
nor direct fibrinogenolytic activity. Two of the replace-
ments had little effect in general, and were not critical for
the specificity of TSV-PA for plasminogen. Nevertheless,
the third replacement produced by conversion of the
sequence Asp96-Asp97-Glu98 to Asn-Val-Ile, significantly
increased the Km for some tripeptide chromogenic sub-
strates and resulted in loss of plasminogenolytic activity,
indicating the key role that this sequence has in substrate
recognition by the enzyme. Separate replacement of each
of these negatively charged residues at the site indicated
that Asp97 was the most critical residue. The Asp97→Val
point mutation resulted in a 125-fold decrease of TSV-PA
activity for plasminogen activation [16]. In our structure,
Asp97 makes a salt bridge to Arg174. Mutational studies
around the segment 172a–176, however, have shown little
or no effect on the plasminogenolytic activity of TSV-PA.
It is therefore reasonable to assume that Asp97 changes its
conformation upon complex formation and participates in
secondary contacts to plasminogen. Noteworthy is the
conservation of Asp97 in uPA and tPA, which only became
apparent upon a structural alignment (Figure 3). It is
likely that Asp97 of tPA and uPA will have a similar role in
plasminogen recognition. 
In contrast to all well characterised trypsin-like serine
proteinases, TSV-PA possesses a phenylalanine residue
instead of a glycine at position 193 (Figures 5 and 6). A
structural alignment with other plasminogen activators
shows that this unusual residue occupies the same posi-
tion as Tyr151 of uPA and tPA, and thereby restricts the
access to the S′2 pocket. It seems likely that this restricted
access to the active-site cleft might be a general mecha-
nism by which plasminogen activators gain substrate
specificity. The activation loop of plasminogen seems to
be held in a peculiar conformation by a disulphide bridge.
This conformation would fit into the restricted active site
of the plasminogen activators, but other ‘extended’ sub-
strates would not. Modelling studies of the plasminogen
activation loop into the active site of TSV-PA support this
view (Figure 4).
Surprisingly, extensive database searches show that a few
other serine proteinases, most of them derived from
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Figure 7
Stereoview stick model of the active site of
TSV-PA. The colours used for TSV-PA are as
described in Figure 5. The reactive-site loops
of turkey ovomucoid inhibitor (green) and
BPTI (white) stretch across the active site. To
the east, residue P′2 (tyrosine) of the turkey
ovomucoid inhibitor clashes with Phe193 of
TSV-PA. A similar situation is seen for residue
P′2 (arginine) of BPTI, which extends through
the aromatic ring of Phe193 in TSV-PA.
Trp173 of TSV-PA occludes the S4 binding
pocket. (The figure was prepared using the
programme MAIN [48].)
snakes, also contain a bulky or charged residue at position
193 (data not shown). Moreover, Nyaruhucha et al. [42]
recently reported the identification and expression of a
human trypsin isoform with an arginine at this position.
These proteinases, including the plasminogen activators,
show partial or no inhibition by BPTI. Inhibitor binding
would be impaired by residue Phe193 of TSV-PA, Arg193
of the trypsin isoform or Tyr151 of the other plasminogen
activators. It is interesting to note that a large number of
the Kunitz- and Kazal-type inhibitors contain an arginine
or lysine at position P′2. The P′2 mainchain of such
canonical inhibitors, as well as the P′2 sidechains, would
collide with the residues from the enzymes mentioned
above. Furthermore, the existence of a trypsin isoform
with inhibitor resistance is intriguing and might be associ-
ated with diseases such as pancreatitis [40]. Mutational
studies should help further define the role of residue 193.
Snake venom serine proteinases have diverged from a
common ancestral molecule and constitute a gene family.
They have evolved in an accelerated manner from glandu-
lar kallikrein to gain functional diversification [23]. The
overall topology of TSV-PA is in good agreement with
these evolutionary relationships. The acquisition of diverse
physiological activities in venom isozymes, however, proves
advantageous to disrupt the integrity of prey animals or to
defend against predators. Thus, snake venom serine pro-
teinases share a high degree of sequence homology (60–
70%) and show at the same time a high substrate speci-
ficity. Due to this high substrate specificity, some venom
components have been put to use as diagnostic reagents or
to characterise molecular defects of haemostasis; other
venom components are, or have the potential to be, thera-
peutic agents [14,43].
TSV-PA exhibit 64% sequence identity to batroxobin
(Figure 3), and the distribution of cysteines is absolutely
conserved. Therefore, our TSV-PA structure provides an
excellent template for modelling batroxobin and other
highly homologous snake venom serine proteinases. More-
over, elucidating specificity differences between closely
related enzymes is a fundamental challenge for both enzy-
mology and drug design. Modelling studies to elucidate
structure/function relationships among these closely related
enzymes are currently underway in our laboratory and will
be presented elsewhere.
In conclusion, the crystal structure of TSV-PA presented
here is the first three-dimensional structure of a snake
venom serine proteinase. The structure provides insight
into the mechanisms by which these enzymes achieve a
high substrate specificity and resistance to inhibition.
Moreover, TSV-PA represents a lead template for accu-
rately modelling other snake venom serine proteinases.
Structural alignments and a model of the interaction
between TSV-PA and the plasminogen activation loop
reveal structural features underlying the specificity of
plasminogen activators. The challenging roles proposed
for residues 193 and 97 prompt mutational studies in tPA
with the potential to design improved fibrinolytic agents.
In addition, the role of residue 193 in disease and in the
design of enzymes with resistance to inhibition should be
further studied.
Biological implications
Snake venom serine proteinases comprise a subfamily of
serine proteinases characterised by a high substrate speci-
ficity and high sequence homology. These enzymes share
a long circulating half-life and a high resistance to protein-
type macromolecular inhibitors, making them interesting
targets for enzymology and drug design. Several of these
proteinases have found commercial application and are
potentially attractive pharmacological tools.
The novel snake venom serine proteinase TSV-PA is a
highly specific plasminogen activator. In an attempt to
understand the determinants of TSV-PA’s substrate
selectivity and resistance to inhibition, we have solved
the crystal structure of TSV-PA in complex with Glu-
Gly-Arg-chloromethylketone. A unique feature of the
structure is the presence of a phenylalanine residue at
position 193. We postulate that this residue accounts for
the observed substrate specificity and the reduced binding
capacities for a series of natural inhibitors. Further-
more, the presence of this residue could also contribute
to a prolonged in vivo plasmin-activating activity.
Mutational studies identified Asp97 of TSV-PA as an
important residue for plasminogen recognition, and struc-
tural alignments reveal that this residue is also con-
served in both types of mammalian plasminogen
activator: tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA). On the
basis of our three-dimensional structure, we postulate
that Asp97 changes its conformation upon complex for-
mation making secondary contacts to plasminogen.
Another interesting structural feature of TSV-PA is a
novel C-terminal extension linked via a disulphide bridge
to a loop (the 99-loop) that lies in close proximity to the
active site. This C-terminal extension is typical for
snake venom serine proteinases although its function is
presently unknown.
In summary, we provide a detailed description of the
TSV-PA structure which explains the high selectivity of
the enzyme towards plasminogen and its resistance to
inhibition. We also identify unique features that make
TSV-PA an interesting template for structure-based
drug design. Moreover, the TSV-PA structure provides
an excellent template for modelling other homologous
snake venom serine proteinases.
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Materials and methods
Protein purification and crystallisation
Recombinant TSV-PA was expressed as inclusion bodies in
Escherichia coli, isolated, refolded and purified as described previously
[16]. TSV-PA (1.1 mg/ml) was inactivated with Glu-Gly-Arg-chloro-
methylketone (Bachem, Bubendorf, Switzerland) or dansyl-Glu-Gly-Arg-
chloromethylketone (Calbiochem, Bad Soden, Germany). To prepare the
complexes, 5 µl of freshly prepared inhibitor solution (0.1 M in dimethyl-
sulphoxide) were added to 1 ml of protein solution (20 mM Tris, 0.2 M
NaCl, pH = 7.0) and incubated at room temperature overnight. The cat-
alytic activities of both complexes were then checked by performing a
chromogenic assay with the substrate S2288 (Chromogenix, Moelndal,
Sweden). No residual activities were found. The complexes were con-
centrated to 7.5 mg/ml using a Centricon 10.
Crystallisation was carried out using the sitting-drop vapour diffusion
method. The drops were composed of 2 µl protein solution and 1 µl of
buffer. The volume of the reservoir was 400 µl. Crystal screenings for
both complexes were carried out at room temperature. In the case of
the dansyl-Glu-Gly-Arg–TSV-PA complex, needles were observed after
four weeks under conditions of 0.1 M Na acetate, 0.2 M (NH4)2SO4
and 25% polyethylene glycol (PEG) 4000 (pH = 4.7). Small crystals
were observed after six weeks in the case of the Glu-Gly-Arg–TSV-PA
complex (0.1 M Na acetate, 0.2 M MgCl2 and 30% PEG 4000
(pH = 4.5)). Further crystallisation experiments were carried out with
the Glu-Gly-Arg–protein complex in order to optimise the quality of the
crystals. Microseeding was performed, but did not lead to the formation
of larger crystals. A pH gradient and a PEG 4000 concentration gradi-
ent were carried out around the initial crystallisation conditions. Crys-
tals suitable for X-ray analysis were obtained with 0.1 M Na acetate,
0.2 M MgCl2 and 25% PEG 4000 (pH = 4.3). Three crystals were har-
vested and diffraction data were collected. The third crystal diffracted
to 2.5 Å resolution and these data were used to solve the structure.
Structure analysis
Diffraction data to 2.5 Å were collected on a MAR image plate system
(MAR Research, Hamburg, Germany) mounted on a Rigaku rotating-
anode X-ray generator and processed with the Mosflm package [44]. A
total of 91 942 reflections were measured and merged to 17 988
unique reflections, with a completeness of 97.7% at 2.5 Å (Table 1).
The crystal belonged to the orthorombic space group P212121, with cell
constants of a = 45.29 Å, b = 67.42 Å and c = 163.67 Å (α =
β = γ = 90°). Estimation of the solvent content indicated that the crystal
contained two molecules per asymmetric unit with a fractional v/v
solvent content of 50% (Vm = 2.44 Å/Da). The structure was solved with
Patterson search techniques. Rotational and translational searches for
the TSV-PA model were performed with AMoRe [45] using data to
3.0 Å and the trypsin component of the bovine β-trypsin–benzamidine
complex as the starting model (PDB accession number 3PTB) [28]. All
nonidentical residues of the trypsin model were changed to alanine. The
rotation function gave one peak at 13.8% correlation, and one peak at
7.9% correlation for the next best angle triplet. The translation function
corresponding to the highest rotation peak yielded a peak at 23.8% cor-
relation for both molecules. A unique solution was found after rigid-body
refinement of both independent molecules, with a correlation value of
36.9% and an R factor of 46.0%. The corresponding figures for the next
best solution were 19.0% and 51.4%.
Conventional crystallographic refinement (rigid-body, positional and tem-
perature-factor) was carried out in several cycles consisting of model-
building performed with the programme O [46] and conjugate gradient
minimisation and simulated annealing using X-PLOR [33]. The target
parameters of Engh and Huber [47] were used. This procedure con-
verged rapidly, yielding a good model (Table 1). Individually restrained
atomic B values were refined and averaging over the noncrystallographic
symmetry elements using X-PLOR provided an improvement of the elec-
tron density (Table 1). A 2σ cut-off and bulk-solvent correction were
applied in the latter stages of the refinement. The electron density
accounting for the inhibitor built in at an R value of 25.9% at 8.0–2.5 Å
resolution was clearly visible before including it in phasing. The bonds
between the covalent inhibitor and the protein (carbonyl carbon–SerOγ
and methylene carbon–His 57Nδ) were realised as a patch residue in
X-PLOR; values for the target bond lengths and angles were taken from
other known structures of serine proteinases with covalently bound
chloromethylketone inhibitors [29,35,48]. Very weak angle restraints
(about one-tenth of the normal values) were chosen for these covalent
inhibitor–protein bonds to allow unbiased angle refinement.
Except for partially undefined surface residues, all atoms were restrained
to obey true noncrystallographic symmetry. Almost all residues of the pro-
teinase domain are defined in the final 2Fobs–Fcalc map. The sidechains of
Lys95, Lys95a, Glu98, Lys148, Glu149, Gln175, His218, Lys245a and
GluI1 are partially disordered and were therefore excluded from phasing;
they are, however, included in the coordinate set. Three cycles of model
building were performed with the program MAIN [34], and ‘quicking’ and
averaging over the noncrystallographic symmetry elements was per-
formed in an attempt to improve the quality of the density around
residues His218 and GluI1. The program PROCHECK [49] indicates
that 87.5% of the residues fall within the most favoured regions of the
Ramachandran plot, and that no residues are in the ‘disallowed regions’.
The secondary structure of TSV-PA was calculated with STRIDE [50]
(Figure 1). Some 5% of the reflections were omitted from the refinement
yielding an R free of 24.4%. Further crystallographic and final model
parameters are given in Table 1.
Accession numbers
The coordinates for TSV-PA have been deposited with the Protein Data
Bank with accession code 1bqy and will be released on the 20th
August 1999.
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Table 1
Statistics for data collection and refinement.
Space group P212121
Cell constants (Å)
a 45.29
b 67.42
c 163.67
Limiting resolution (Å) 2.5
Reflections measured 91 942
Rmerge (%)* overall 10.2
Rmerge (%)* outermost shell (2.49 Å) 44.4
Unique reflections 17 988
Completeness (%) overall 97.7
Completeness (%) outermost shell (2.49 Å) 82.1
Nonhydrogen protein atoms 1797
Nonhydrogen inhibitor atoms 25
Solvent molecules 207
Reflections used for refinement 17 215
Resolution range (Å) 100–2.5
Completeness (%) overall (100–2.5 Å) 95.3
Completeness (%) outermost shell (2.5–2.59 Å) 90.6
R value (%)† overall (100–2.5 Å) 17.8
R value (%)† outermost shell (2.5–2.59 Å) 35.2
R free (%)‡ 24.4
Rms standard deviations
bond length (Å) 0.009
bond angles (°) 1.86
NCS deviation of Cα atoms (Å) 0.069
*Rmerge = [ Σh Σi |I(h,i) – < I(h) >| I Σh Σi I(h,i)] × 100, where I(h,i) is
the intensity value of the ith measurement of h and < I(h)> is the
corresponding mean value of h for all i measurements of h. The
summation is over all measurements. †R value = (Σ|Fo – Fc| / ΣFo) ×
100. ‡R free was calculated randomly omitting 5% of the observed
reflections from the refinement and R factor calculation (see text).
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